Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
| ▸ | AMY2A | P04746 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IGF2R | P11717 | 2/20 | 0.38 |
| ▸ | TYR | P14679 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maltose SCHEMBL9296676 | 1.00 | LGALS8 (0.44) | LGALS8LGALS3LGALS4AMY2AMEN1 | |
| Cellobiose SCHEMBL17941750 | 1.00 | LGALS8 (0.44) | LGALS8LGALS3LGALS4AMY2AMEN1 | |
| Cellobiose SCHEMBL4302484 | 1.00 | LGALS8 (0.44) | LGALS8LGALS3LGALS4AMY2AMEN1 | |
| Demannose SCHEMBL8488325 | 1.00 | LGALS8 (0.44) | LGALS8LGALS3LGALS4AMY2AMEN1 | |
| Maltose SCHEMBL537670 | 1.00 | LGALS8 (0.44) | LGALS8LGALS3LGALS4AMY2AMEN1 | |
| Cellobiose SCHEMBL23699869 | 1.00 | LGALS8 (0.44) | LGALS8LGALS3LGALS4AMY2AMEN1 | |
| Maltose SCHEMBL7601981 | 1.00 | LGALS8 (0.44) | LGALS8LGALS3LGALS4AMY2AMEN1 | |
| Maltose SCHEMBL9738256 | 1.00 | LGALS8 (0.44) | LGALS8LGALS3LGALS4AMY2AMEN1 | |
| Cellobiose SCHEMBL16058825 | 1.00 | LGALS8 (0.44) | LGALS8LGALS3LGALS4AMY2AMEN1 | |
| Demannose SCHEMBL8489805 | 1.00 | LGALS8 (0.44) | LGALS8LGALS3LGALS4AMY2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209115-A1 | METHODS FOR REDUCING LOW MOLECULAR WEIGHT SPECIES OF RECOMBINANTLY-PRODUCED PROTEINS | AMGEN INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4330281-A1 | METHODS FOR REDUCING LOW MOLECULAR WEIGHT SPECIES OF RECOMBINANTLY-PRODUCED PROTEINS | Amgen Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230398147-A1 | METHODS FOR ADMINISTERING THERAPEUTIC DOSES OF BISPECIFIC T-CELL ENGAGING MOLECULES FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2023183231-A1 | COMBINATION THERAPY METHODS WITH T-CELL ENGAGING MOLECULES FOR TREATMENT OF PROSTATE CANCER | AMGEN INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4214233-A1 | METHODS FOR ADMINISTERING THERAPEUTIC DOSES OF BISPECIFIC T-CELL ENGAGING MOLECULES FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230020514-A1 | METHODS FOR TREATING OR PREVENTING MIGRAINE HEADACHE | AMGEN INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220389099-A1 | METHODS FOR TREATING LEUKEMIA | AMGEN INC. (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2022060878-A1 | METHODS FOR TREATING PROSTATE CANCER | AMGEN INC. (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20210161860-A1 | IMMUNOSUPPRESSANT FORMULATION | NOVARTIS AG (CH) | 2021-06-03 | — | — | US | disclosed |
| EP-3774881-A1 | ERENUMAB COMPOSITIONS AND USES THEREOF | Amgen Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3285803-A1 | METHODS FOR TREATING OR PREVENTING MIGRAINE HEADACHE | Amgen Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-3129006-A1 | IMMUNOSUPPRESSANT FORMULATION | Novartis AG (CH) | 2017-02-15 | — | — | EP | disclosed |
| US-20170027906-A1 | IMMUNOSUPPRESSANT FORMULATION | NOVARTIS PHARMA AG (CH) | 2017-02-02 | — | — | US | disclosed |
| WO-2016171742-A1 | METHODS FOR TREATING OR PREVENTING MIGRAINE HEADACHE | AMGEN INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311913-A1 | METHODS FOR TREATING OR PREVENTING MIGRAINE HEADACHE | AMGEN INC. (US) | 2016-10-27 | — | — | US | disclosed |
| WO-2015155711-A1 | IMMUNOSUPPRESSANT FORMULATION | NOVARTIS AG (CH) | 2015-10-15 | — | — | WO | disclosed |
| EP-0518976-A4 | FUNGICIDAL COMPOSITIONS FOR APPLICATION TO PLANTS | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0518976-A1 | FUNGICIDAL COMPOSITIONS FOR APPLICATION TO PLANTS. | TATE DAVID (AU) | 1992-12-23 | — | — | EP | disclosed |
| WO-1991013552-A1 | FUNGICIDAL COMPOSITIONS FOR APPLICATION TO PLANTS | TATE DAVID (AU) | 1991-09-19 | — | — | WO | disclosed |
| US-3939279-A | YEASTS; ALGAE | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161860-A1 | IMMUNOSUPPRESSANT FORMULATION | IL2, ICOS, TSLP | LGALS8 1520/4885LGALS3 2288/4885LGALS4 1682/4885 |
| US-20170027906-A1 | IMMUNOSUPPRESSANT FORMULATION | IL2, ICOS, TSLP | LGALS8 1520/4885LGALS3 2288/4885LGALS4 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.